Uniting European Cell Engager & Bispecific Antibody Leaders to Optimise Targeting, Safety & Translational Research in Oncology & Autoimmune Indications
Fresh from the success of our Boston meeting, we’re bringing the momentum to Europe for the very first time. This dedicated forum will unite leading minds in preclinical research, translational science, immunology, and oncology drug development to unlock the full potential of T-cell engagers and accelerate their path to the clinic.
The field is moving at unprecedented speed: with 8 TCE approvals, the space is attracting record investment and partnerships – AbbVie’s $2.1B deal with Xilio and Sanofi’s €15M partnership with Innate Pharma being just two recent examples. As pharma and biotech double down on next-generation immunotherapies, the race is on to push the boundaries of what TCEs can achieve.
But challenges remain. Target selection, bioavailability, immunogenicity, and translational hurdles continue to limit therapeutic windows, while the expansion into autoimmune disease opens new complexities and opportunities. This summit will bring together the leaders driving innovation to overcome these barriers and redefine the future of TCEs.
The conference was hyper focused and really provided a good sense of what the current cell engager landscape was. I also appreciated the directed networking time and felt that with such a small group it was easy to get to know people and learn about what is in the pipeline. – InhibRx
It was great to have many opportunities to network with folks. I especially enjoyed the breadth and quality of the talks. – Boehringer Ingelheim
Enjoyed meeting with others who work in the same field and discussing opportunities and challenges with them. – Pfizer
Join your peers to:
- Unlock synergistic potential – Hear from Regeneron and Zymeworks on how co-stimulation strategies (CD28, CD137, CD2) can supercharge T cell fitness and cytotoxic responses.
- Tackle preclinical limitations – Learn from Amgen, Roche, and NovalGen on addressing hyperactivated T cells and improving translatability.
- Go beyond traditional engagers – Explore novel modalities including AstraZeneca’s TITAN nanobody platforms, BIOMUNEX’s MAIT engagers, and NK cell engagers from Peipp’s lab.
- Expand into autoimmunity – Gain insights from Cullinan, IN8Bio, and Cue Biopharma as they share clinical and preclinical progress in targeting B cell subsets and pathogenic immune cells.
This is your opportunity to join the first-ever European community dedicated to T-cell engagers, where science, strategy, and collaboration converge to drive the next generation of immunotherapies.
Explore the Full Event Guide
- Benchmark the latest clinical and preclinical insights shaping next-generation TCE development in oncology and autoimmunity
- Translate innovative design strategies, from co-stimulation to masked and logic-gated TCEs into improved specificity, potency, and safety
- Equip yourself with solutions to overcome translational and preclinical challenges, including hyperactivated T cells and unrealistic tumour clearance models
- Connect with leading biopharma, biotech, and academic pioneers driving novel modalities such as TITAN nanobodies, MAIT engagers, and NK cell engagers
- Position your team at the forefront of emerging therapeutic opportunities, with firsthand insights into investment trends, partnerships, and expansion into autoimmune disease
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into cutting-edge T-cell engager science with insights from leading biopharma, biotech, and academic experts.
Partner With Us
Showcase your technologies and services to decision-makers driving next-generation TCE innovation.
Join Biopharma Experts
Be part of the only European meeting uniting immunology, biology, preclinical, and translational experts in the TCE space.